Mon panier

Angiopoietin-like 3

Angiopoietin-like 3 Informations sur la molécule

Nom anglaisAngiopoietin like 3Nombre de médicaments commercialisés1
Nombre de médicaments cliniques14Alias de la cibleAngiopoietin Like 3,Angiopoietin 5,UNQ153/PRO179,Angiopoietin-5,Angiopoietin-like protein 3,ANGPT5,ANG-5,Angiopoietin-Related Protein 3,Angiopoietin-Like 3,FHBL2,ANL3,ANGPTL3
Phase de R&D la plus avancéeApproved
Nom anglaisAngiopoietin like 3
Alias de la cibleAngiopoietin Like 3,Angiopoietin 5,UNQ153/PRO179,Angiopoietin-5,Angiopoietin-like protein 3,ANGPT5,ANG-5,Angiopoietin-Related Protein 3,Angiopoietin-Like 3,FHBL2,ANL3,ANGPTL3
Nombre de médicaments commercialisés1
Nombre de médicaments cliniques14
Phase de R&D la plus avancéeApproved

Angiopoietin-like 3 Liste de produits

  • Attribut

    Protein (5)

  • Bibliothèque de produits

    En ligne (5)

  • Espèces

    Human (4)Mouse (1)

  • Étiquette

    His Tag (3)His Tag & Avi Tag (1)Fc Tag (1)

  • Marqueur

    Unconjugated (4)Biotin-labeled (1)

Angiopoietin-like 3Contexte de la molécule

Angiopoietin-like protein 3 (ANGPTL3) is also known as Angiopoietin-related protein 3, Angiopoietin-5 (ANGPT5 / ANG-5), is a member of the angiopoietin-like family of secreted factors. ANGPTL3 / ANGPT5 is predominantly expressed in the liver, and has the characteristic structure of angiopoietins, consisting of a signal peptide, N-terminal coiled-coil domain and the C-terminal fibrinogen (FBN)-like domain. The FBN-like domain in angiopoietin-like 3 protein was shown to bind alpha-5/beta-3 integrins, and this binding induced endothelial cell adhesion and migration. This protein may also play a role in the regulation of angiogenesis. Angptl3 also acts as dual inhibitor of lipoprotein lipase (LPL) and endothelial lipase (EL), and increases plasma triglyceride and HDL cholesterol in rodents. ANGPTL3 inhibit endothelial lipase to catalyze HDL-phospholipid and increase HDL-PL levels. Circulating PL-riched HDL particles have high cholesterol efflux abilities.

Angiopoietin-like 3Alias de la molécule

ANGPTL3,ANGPT5,ANG-5,Angiopoietin-5,FHBL2

Informations sur les médicaments cliniques

Nom anglaisCode de recherchePhase de R&DEntrepriseIndicationEssai clinique
ZodasiranARO-ANG3; ARO-ANG33; VSA-003 (Arrowhead Pharmaceuticals)Phase 3 ClinicalRoche LtdDyslipidemias; Homozygous familial hypercholesterolemia; Hypercholesterolemia; Hyperlipoproteinemia Type II; Hypertriglyceridemia
Details
LNA-043LNA-043Phase 2 ClinicalNovartis Pharma AgKnee Injuries; Osteoarthritis; Osteoarthritis, Knee
Details
VupanorsenISIS-703802; PF-07285557Phase 2 ClinicalIonis Pharmaceuticals IncCardiovascular Diseases; Diabetes Mellitus, Type 2; Dyslipidemias; Homozygous familial hypercholesterolemia; Hyperlipidemias; Hyperlipoproteinemia Type I; Hyperlipoproteinemia Type II; Hyperlipoproteinemias; Hypertriglyceridemia; Metabolic Dysfunction-Associated Steatotic Liver Disease
Details
EDP-167EDP-167; EDP167Phase 2 ClinicalEteng Pharmaceutical (Zhuhai) Co LtdDyslipidemias; Homozygous familial hypercholesterolemia
Details
ALN-ANG3ALN-ANG3Phase 2 ClinicalAlnylam Pharmaceuticals IncDiabetic Nephropathies
Details
BW-00112BW-00112; BW00112Phase 2 ClinicalShanghai Argo Biopharmaceutical Co LtdDyslipidemias; Hypertriglyceridemia
Details
SolbinsiranLY-3561774; DCR-CM-1; DCR-CM1Phase 2 ClinicalDicerna Pharmaceuticals IncCardiovascular Diseases; Dyslipidemias; Hyperlipoproteinemias; Hypertriglyceridemia; Lipid Metabolism Disorders; Metabolic Diseases
Details
JS-401JS-401; RP-912Phase 1 ClinicalRisen (Suzhou) Pharma Tech Co LtdHyperlipidemias; Metabolic Diseases
Details
VERVE-201VERVE-201Phase 1 ClinicalBroad Institute, Harvard UniversityAtherosclerosis; Homozygous familial hypercholesterolemia; Hypercholesterolemia; Hypertriglyceridemia
Details
SYH-2070SYH2070; SYH-2070Phase 1 ClinicalCspc Heibei Zhongrun Pharmaceutiacl Co LtdHyperlipidemia, Familial Combined; Hyperlipidemias; Hypertriglyceridemia
Details
NN-6491NN6491; NN-6491Phase 1 ClinicalNovo Nordisk A/SCardiovascular Diseases
Details
NNC0491-6075NNC0491-6075; NNC04916075Phase 1 ClinicalNovo Nordisk A/SDyslipidemias
Details
AZD-1705AZD1705; AZD-1705Phase 1 ClinicalAstrazeneca Plc, Parexel International CorpCardiovascular Diseases
Details
CTX-310CTX-310; CTX310Phase 1 ClinicalCrispr Therapeutics AgCardiovascular Diseases; Dyslipidemias; Heterozygous familial hypercholesterolemia; Homozygous familial hypercholesterolemia; Hypercholesterolemia; Hyperlipidemias; Hypertriglyceridemia; Lipid Metabolism Disorders; Metabolic Diseases; Sitosterolemia
Details

Informations sur les médicaments commercialisés

Nom anglaisCode de recherchePhase de R&DEntreprisePlus ancien nom de marquePays d'approbation le plus ancienIndication la plus ancienneSociété d'approbation la plus ancienneDate d'approbation la plus ancienneIndicationEssai clinique
EvinacumabREGN-1500ApprovedRegeneron Pharmaceuticals IncEvkeezaUnited StatesHypercholesterolemia; Homozygous familial hypercholesterolemiaRegeneron Pharmaceuticals Inc2021-02-11Homozygous familial hypercholesterolemia; Hypercholesterolemia; Hypertriglyceridemia; Metabolic Diseases
Details
  • Informations sur la molécule
  • Liste de produits
  • Informations sur les médicaments commercialisés
  • Informations sur les médicaments cliniques